ARTICLE | Clinical News
Arimoclomol: Phase III started
June 27, 2016 7:00 AM UTC
Orphazyme began the double-blind, placebo-controlled, international Phase III NPC-002 trial to evaluate oral arimoclomol thrice daily plus standard of care (SOC) for 12 months in about 46 patients. ...